Kaposi sarcoma · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | local_therapy |
| Linked regimen | None |
| ID | IND-KAPOSI-1L-CLASSIC-LOCAL-OBSERVATION |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-KAPOSI |
| Sources | SRC-IARC-MONO-100B-2012 SRC-NCCN-SKIN-2025 |
Notes
STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation), covering classic and endemic forms. Deliberately has `recommended_regimen: null` -- the disease narrative specifies only "local therapy or observation" without a preferred modality or dose, and CHARTER §8.3 prohibits inventing one; local-therapy modality selection is left to MDT/dermatology-oncology discretion pending future authoring of a dedicated local-therapy Regimen/Surgery/ RadiationCourse entity if the clinical co-leads want one formalized. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports" and populated the `known_controversies[].positions[].sources` with the same id. That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record), not classic/ endemic Kaposi management -- downgraded the top-level citation to "context" and removed it from the controversy positions (no verifiable source for either side of that controversy exists in this KB, so left empty rather than fabricated). Pending two-Clinical- Co-Lead signoff (CHARTER §6.1 -- dev-mode-exempted; safe to merge as draft content, NOT...
Used By
Algorithms
ALGO-KAPOSI-1L- ALGO-KAPOSI-1L
Disease
DIS-KAPOSI- Kaposi sarcoma